Very interesting play here with the companies latest trial results,now open to ongoing Phase II and likely partners.
Cyclacel Pharmaceuticals to Present at the 22nd Annual ROTH Capital OC Growth Stock Conference
10:04a ET March 8, 2010 (GlobeNewswire)
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that the Company will present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference being held at The Ritz Carlton in Laguna Niguel, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, March 15, 2010 at 2:00 p.m. Pacific.
Cyclacel's presentation will be webcast live and archived for 90 days on the Corporate Presentations page of the Cyclacel website at www.cyclacel.com.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Cyclacel Pharmaceuticals, Inc. (CYCC) announced this morning that a recent study at the University of Texas has shown that its seliciclib drug may potentially treat breast cancer cells that are resistant to hormone therapy. The drug is currently in Phase 2 trials. The report has pushed Cyclacel shares up nearly 13% in early trading on very heavy volume.
Cyclacel is a relatively small player in a field of biotech giants that includes Amgen Inc. (AMGN), Gilead Sciences Inc. (GILD) and Celgene Corp. (CELG). And with a share price still below $3 and a market cap of about $70 million, Cyclacel could be a takeover target for one of the bigger players.
Seliciclib has been shown to kill breast cancer cells that are resistant to aromatase inhibitors such as letrozole, a drug manufactured by Novartis AG (NVS) and marketed under the trade name Femara.
The interesting thing here is that a new patentable drug has been shown to have promise. During the next few years, a large number of best-selling drugs will lose patent protection and the big pharmaceutical houses need to replenish their supply of patents.
If a drug is already developed and is proving to be useful, it is probably cheaper to buy the rights than it is to develop a competing drug from scratch. Certainly it is potentially faster, provided that no negative surprises surface during trials.
The other potential problem, at least from an investor's point of view, is government intervention. The laws protecting patented drugs could be relaxed, allowing generics to enter the market more quickly and reducing profits to patent owners.
Big pharma needs to figure out a way to guard against such changes, and perhaps the simplest solution is to partner with or buy a smaller company that is well into the late stages of clinical trials.
Biotech firms will also be doing more than just creating new drugs. It is almost certain that some firms, and probably the smaller ones, will be identifying genetic markers that will help determine who is likely to get a certain disease and how that person will respond to a specific drug.
The positioning for the next five years begins now.
Market Data 
Markets 
AI
